Dan Gliddon
Chief Operations Officer @Forcefield Therapeutics
Signup · Get unlimited contacts
WORK HISTORY
Chief Operations Officer @Forcefield Therapeutics
London, GB
Pioneer of gene and biological therapeutic approaches for chronic heart failure and cardiovascular disease- Led end-to-end CVRM strategy for novel gene therapy and protein therapeutics targeting acute and chronic heart disease and cardiometabolic disease- Chaired development program teams coordinating strategy across CMC, pharmacology, regulatory, clinical development, and commercial functions- Formed and led clinical advisory board of world-class cardiovascular experts providing strategic guidance on competitive positioning- Executed competitive intelligence strategy - Spearheaded £30+M Series A fundraising, securing European & strategic investors through compelling CVRM value proposition- Negotiated strategic licensing partnership with Freeline Therapeutics for gene therapy collaboration
EDUCATION
University of Reading
Bachelor of Science (BSc)
Royal Postgraduate Medical School (RPMS), Imperial College School of Medicine (ICSM)
Master of Science (MSc)
University of Reading:Institute for Animal Health
PhD
SKILLS
ABOUT DAN GLIDDON
Building the next generation of breakthrough biological therapeutics across cardiovascular, immunology, and gene therapy platforms 🧬As COO & Strategic Leader at Forcefield Therapeutics, I\'m pioneering protein and gene therapy approaches for heart disease while leveraging 15+ years of cross-therapeutic strategic leadership spanning immunology, oncology, and CVRM. THERAPEUTIC PLATFORM EXPERTISE- CVRM: Gene and biologic therapies for acute and chronic heart diesase and adjacent areas e.g metabolic disease- Immunology/Oncology: Bispecific antibodies, immune checkpoint inhibitors, translational medicine- Cross-platform strategy: Portfolio prioritization, competitive intelligence, regulatory pathways PROVEN STRATEGIC LEADERSHIP- Led £30+M Series A with compelling multi-therapeutic value proposition- Led clinical advisory boards across cardiovascular programmes- Built 20+ person cross-functional teams spanning discovery to clinical PoC- Advanced assets from discovery through Phase 3 across multiple therapeutic areas CORE COMPETENCIESStrategic Leadership | Portfolio Strategy | Biological and Gene Therapies | CVRM | Immunology | Cross-functional Teams | FundraisingReady to discuss breakthrough therapeutic strategies across disease areas. d•••••••@hotmail.com
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.